A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors.

Authors: Roisin Eilish O'Cearbhaill, Minal A. Barve, Christopher Darus, Nashat Y. Gabrail, Paul Johannet, Jade Loh, MaryBeth LeRose, Karen Andreas, Claudio Dansky Ullmann

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2685

Source: Full article

---

Abstract

TPS2685